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Introduction {#jgh312141-sec-0001}
============

The development of a fistula track is a relatively common feature of Crohn\'s disease (CD) and is responsible for a large proportion of its morbidity.[1](#jgh312141-bib-0001){ref-type="ref"} Perianal fistulas can be particularly challenging due to severe symptoms such as pain, embarrassing discharge, and incontinence, with a significant reduction of quality of life.[2](#jgh312141-bib-0002){ref-type="ref"} Today, combined medical and surgical therapy is understood to perform better than either treatment alone in achieving fistula healing.[3](#jgh312141-bib-0003){ref-type="ref"} However, the benefit in terms of sustained fistula closure has proven to be limited, with a relapse rate of 16% at 1 year, 31% at 3 years, and 40% at 5 years.[4](#jgh312141-bib-0004){ref-type="ref"}, [5](#jgh312141-bib-0005){ref-type="ref"} In addition, the need to use biological agents, even in association with conventional immunosuppressants, carries an increased risk of opportunistic infections and other complications.[6](#jgh312141-bib-0006){ref-type="ref"} Unrelated to CD, a second and more common etiology of perianal fistulas is cryptoglandular. These are generally easily managed surgically but sometimes display the same anatomic complexity and difficulty to treat as those related to CD.[7](#jgh312141-bib-0007){ref-type="ref"}

In the recent past, the use of mesenchymal stem cell (MSC) injections in the fistula tract has yielded promising results.[8](#jgh312141-bib-0008){ref-type="ref"}, [9](#jgh312141-bib-0009){ref-type="ref"}, [10](#jgh312141-bib-0010){ref-type="ref"}, [11](#jgh312141-bib-0011){ref-type="ref"} MSCs are multilineage somatic progenitor cells endowed with unique biological properties, including the lack of substantial immunogenicity that allows use across human leukocyte antigen (HLA) barriers[12](#jgh312141-bib-0012){ref-type="ref"}, homing toward sites of active inflammation[13](#jgh312141-bib-0013){ref-type="ref"} and regenerative capacity.[14](#jgh312141-bib-0014){ref-type="ref"} Most importantly, MSCs also exert an extraordinary immunomodulating action on all cells involved in immune response, with the ultimate effect of dampening inflammation while restoring tolerance.[15](#jgh312141-bib-0015){ref-type="ref"} Taken together, these properties make MSCs particularly suitable for the treatment of conditions characterized by both chronic inflammation and tissue damage, such as fistulas in CD. Following a number of observational studies and case series,[8](#jgh312141-bib-0008){ref-type="ref"}, [9](#jgh312141-bib-0009){ref-type="ref"}, [10](#jgh312141-bib-0010){ref-type="ref"}, [11](#jgh312141-bib-0011){ref-type="ref"} a phase III double‐blind clinical trial was carried out on 212 patients with nonactive or mildly active CD and complex perianal fistulas refractory to at least one conventional or biological therapy who were randomly assigned to receive one local injection of adipose‐derived MSCs (darvadstrocel, formerly Cx601) or a placebo.[16](#jgh312141-bib-0016){ref-type="ref"} Those patients who were administered darvadstrocel had a significantly higher rate of combined remission at week 24,[16](#jgh312141-bib-0016){ref-type="ref"} extending to 52 weeks.[17](#jgh312141-bib-0017){ref-type="ref"} This has led to a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency regarding using this product to treat complex perianal fistulas in adults with CD upon an inadequate response to at least one conventional or biologic therapy. Therefore, we aimed to carry out a systematic literature review and meta‐analysis of all the data published to evaluate the safety and efficacy of local injections of MSCs in patients suffering with CD and cryptoglandular fistulas, with the goal of helping to clarify the correct placement of this novel treatment option in the therapeutic algorithm.

Materials and methods {#jgh312141-sec-0002}
=====================

*Protocol registration* {#jgh312141-sec-0003}
-----------------------

The study protocol was developed according to the PRISMA‐P guidelines[18](#jgh312141-bib-0018){ref-type="ref"} and was also registered on the PROSPERO website with the number CRD42017076213, which can be accessed on <https://www.crd.york.ac.uk/PROSPERO/>. A statistical analysis plan was finalized before data extraction and analysis.

*Information sources and literature search* {#jgh312141-sec-0004}
-------------------------------------------

This systematic review was conducted and reported in accordance with the PRISMA guidelines.[19](#jgh312141-bib-0019){ref-type="ref"} We searched the literature as follows: (i) using electronic databases MEDLINE/PubMed, EMBASE, Web of Science, Cochrane databases, CINAHL, and [ClinicalTrials.gov](http://clinicaltrials.gov); (ii) hand search of the ECCO 2017 congress proceedings; and (iii) personal knowledge. The search strategy is summarized in Tables S1 A,B, Supporting information. Only original articles and abstracts were selected. Reviews, letters, and meta‐analyses were not considered. All relevant articles published through May 15th, 2017 in English, Italian, French, Spanish, or German were considered.

*Study selection and data collection* {#jgh312141-sec-0005}
-------------------------------------

An initial study selection was performed by the librarian based on the eligibility criteria and the content of the abstract; the selection was supervised and refined by the first author (RC), and full texts were downloaded and stored locally. The data were independently retrieved by two authors (RC and CK), and all discrepancies were resolved through a joint session by reexamining the papers. A third author (GRC) was available to reach an agreement if needed. Data were collected into a database set up in REDCap^©^ (Research Electronic Data Capture),[20](#jgh312141-bib-0020){ref-type="ref"} a secure web‐based platform, and were subsequently exported into Stata 14 (Stata Corporation, College Station; TX, USA) for analysis. Information on study design, study quality, availability of the chosen end‐points, number of patients, and clinical characteristics of the population was retrieved.

*Eligibility inclusion criteria* {#jgh312141-sec-0006}
--------------------------------

We included randomized clinical trials (RCTs) and one‐arm clinical trials or cohort studies on patients with CD or cryptoglandular fistulas, treated with local injection(s) of autologous or allogeneic MSCs from any source (alone or *versus* placebo/comparator or standard of care). Any dose and follow‐up duration was considered.

The following safety end‐points were included:Number of patients with adverse events (AEs).Number of patients with treatment‐related AEs.Number of patients with severe treatment‐related AEs.Number of patients with local acute AEs.Number of patients with local late AEs.Number of patients with systemic acute AEs.Number of patients with systemic late AEs.Number of AEs per patient per month.Number of treatment‐related AEs per patient per month.Number of severe treatment‐related AEs per patient per month.Death and hospitalizations.

The following efficacy end‐points were retrieved from the articles (as available):12External healing (complete or partial) based on surgical inspection. In this regard, a fistula track was considered clinically 'closed' when it no longer drained despite gentle finger compression; fistula remission was defined as the absence of any draining fistula opening, and response was defined as a reduction of 50% or more in the number of draining fistulas.13Clinical assessment: calculation of clinical indexes of activity, that is, Crohn\'s Disease Activity Index (CDAI[21](#jgh312141-bib-0021){ref-type="ref"}) and Perianal Disease Activity Index (PDAI[22](#jgh312141-bib-0022){ref-type="ref"}).14Deep fistula healing (radiological healing) based on magnetic resonance imaging (MRI) as evaluated according to the categories and score proposed by van Assche *et al*.[23](#jgh312141-bib-0023){ref-type="ref"} if available; otherwise, deep healing was considered based on the description reported in the manuscript.15Mucosal healing by endoscopic examination if available.16Clinical composite score \[combination of (1) and (3)\].17Fistula recurrence.

*Risk of bias* {#jgh312141-sec-0007}
--------------

Each individual study was assessed for the risk of bias. For RCTs, the risk of bias was assessed at the study level using the Cochrane risk‐of‐bias assessment instrument.[24](#jgh312141-bib-0024){ref-type="ref"} Biases were assessed across four domains: random sequence generation, allocation concealment, incomplete outcome data, and selective reporting. The corresponding protocols were examined if published. For one‐arm clinical trials and cohort studies, we considered both the incomplete outcome data and methods for controlling confounding items. Each item was classified as having either a high, low, or unclear risk of bias. A second, subjective, assessment of bias used a 0--100 (with 100 being the best) visual analog scale (VAS) and accounted for study design (RCT ranked highest), complete information provided on efficacy (for instance, number of patients for each end‐point), and complete information provided on safety (for instance, number of patients/events for each safety end‐point). The reported VAS for each study was the mean of two authors'/reviewers' evaluations (RC and CK).

*Summary measures and synthesis of results* {#jgh312141-sec-0008}
-------------------------------------------

Patients' characteristics were summarized using the median and 25--75th percentiles. Within each study and for each study arm (as applicable), the cumulative incidence of events was calculated as the ratio of the total number of patients with events over the total number of patients overall and in each study arm. The monthly incidence rate was calculated as the total number of events over the total number of patients per month in each arm. The time horizon for acute events (healing and AEs) was set at 2 months, and the median study follow‐up was used for late events. For comparative studies, the relative risk (RR) with its 95% confidence interval (95% CI) for each categorical outcome and the standardized mean difference (SMD, computed from the reported mean difference and standard deviation \[SD\]) for continuous outcomes were derived from the available data. At least three studies were required to derive RR and SMD. For comparative studies, study RR and SMD were pooled according to the DerSimonian and Laird random effects model.[25](#jgh312141-bib-0025){ref-type="ref"} To this end, single‐arm study cumulative rates and Poisson‐based rates over time estimates were retrieved/calculated. Statistical heterogeneity among studies was assessed using the Cochran Q test and measured by the I‐squared statistic. The presence of publication bias was investigated by the possible asymmetry in the funnel plot. Data were analyzed with Stata 14.

Results {#jgh312141-sec-0009}
=======

*Study selection* {#jgh312141-sec-0010}
-----------------

As shown in the flowchart in Figure [1](#jgh312141-fig-0001){ref-type="fig"}, the bibliographic search identified 345 articles, leaving 211 (inclusive of 41 abstracts) after duplicate removal. Twenty full‐text articles and six abstracts were examined for inclusion. After review, an additional three full‐text articles were removed, and a total of 23 studies (17 studies including three substudies and six abstracts) were retained for the review and meta‐analysis.

![PRISMA flowchart showing study disposition from the bibliographic yield.](JGH3-3-249-g001){#jgh312141-fig-0001}

*Study characteristics* {#jgh312141-sec-0011}
-----------------------

As detailed in Table [1](#jgh312141-tbl-0001){ref-type="table"}, of the 23 publications describing studies,[8](#jgh312141-bib-0008){ref-type="ref"}, [9](#jgh312141-bib-0009){ref-type="ref"}, [10](#jgh312141-bib-0010){ref-type="ref"}, [11](#jgh312141-bib-0011){ref-type="ref"}, [16](#jgh312141-bib-0016){ref-type="ref"}, [17](#jgh312141-bib-0017){ref-type="ref"}, [26](#jgh312141-bib-0026){ref-type="ref"}, [27](#jgh312141-bib-0027){ref-type="ref"}, [28](#jgh312141-bib-0028){ref-type="ref"}, [29](#jgh312141-bib-0029){ref-type="ref"}, [30](#jgh312141-bib-0030){ref-type="ref"}, [31](#jgh312141-bib-0031){ref-type="ref"}, [32](#jgh312141-bib-0032){ref-type="ref"}, [33](#jgh312141-bib-0033){ref-type="ref"}, [34](#jgh312141-bib-0034){ref-type="ref"}, [35](#jgh312141-bib-0035){ref-type="ref"}, [36](#jgh312141-bib-0036){ref-type="ref"}, [37](#jgh312141-bib-0037){ref-type="ref"}, [38](#jgh312141-bib-0038){ref-type="ref"}, [39](#jgh312141-bib-0039){ref-type="ref"}, [40](#jgh312141-bib-0040){ref-type="ref"}, [41](#jgh312141-bib-0041){ref-type="ref"}, [42](#jgh312141-bib-0042){ref-type="ref"} 6 were RCTs. Of these, one[17](#jgh312141-bib-0017){ref-type="ref"} was a substudy of a previous RCT[16](#jgh312141-bib-0016){ref-type="ref"} that compared MSC treatment with placebo, and one study,[29](#jgh312141-bib-0029){ref-type="ref"} where two dosages of MSCs were randomly used, reported only collapsed results, leaving four RCTs available for comparison. Of these, three studies compared MSCs to placebo, while one study compared MSCs to fibrin glue. Ten studies were one‐arm clinical trials, and seven were observational (with two substudies). Thirteen studies (65%) were multicenter.

###### 

Studies included in the review and meta‐analysis

  First author (reference number)                                                                                                          Year   Multicenter        Substudy                 Design           Phase/number of arms             Arm combination             Total number patients/months of follow‐up
  --------------------------------------------------------------------------------------------------------------------------------------- ------ ------------- --------------------- ------------------------ ---------------------- ------------------------------------- -------------------------------------------
  Garcia‐Olmo D [26](#jgh312141-bib-0026){ref-type="ref"}                                                                                  2010       No                                   Case series                ---/1                           MSC                                      1/1
  Cho YB [27](#jgh312141-bib-0027){ref-type="ref"}                                                                                         2013       Yes                             One‐arm clinical trial           I/1                            MSC                                     10/2
  Lee WY [11](#jgh312141-bib-0011){ref-type="ref"}                                                                                         2013       Yes                             One‐arm clinical trial           II/1                           MSC                                     43/2
  Cho YB [28](#jgh312141-bib-0028){ref-type="ref"}                                                                                         2015       Yes          Lee WY, 2013         Cohort univariable            ---/1                           MSC                                     41/24
  Choi S[†](#jgh312141-note-0004){ref-type="fn"} ^,^ [‡](#jgh312141-note-0005){ref-type="fn"} [29](#jgh312141-bib-0029){ref-type="ref"}    2013       Yes                                      RCT                     II/2                    Low MSC, high MSC                              15/2
  Molendijk I [30](#jgh312141-bib-0030){ref-type="ref"}                                                                                    2015       Yes                                      RCT                     II/2                      Placebo, MSC                                 21/3
  Panes J [16](#jgh312141-bib-0016){ref-type="ref"}                                                                                        2016       Yes                                      RCT                    III/2                      Placebo, MSC                                 212/6
  Garcia‐Olmo D [8](#jgh312141-bib-0008){ref-type="ref"}                                                                                   2005       No                              One‐arm clinical trial           I/1                            MSC                                      5/2
  Garcia‐Olmo D [32](#jgh312141-bib-0032){ref-type="ref"}                                                                                  2003       No                                   Case series                ---/1                           MSC                                      1/3
  Garcia‐Olmo D [31](#jgh312141-bib-0031){ref-type="ref"}                                                                                  2009       Yes                                      RCT                     II/2                      Placebo, MSC                                 50/2
  Herreros MD[§](#jgh312141-note-0006){ref-type="fn"} [33](#jgh312141-bib-0033){ref-type="ref"}                                            2012       Yes                                      RCT                    III/3           MSC, MSC + fibrin glue, fibrin glue                     200/6
  Ciccocioppo R [9](#jgh312141-bib-0009){ref-type="ref"}                                                                                   2011       No                                Cohort univariable            ---/1                           MSC                                     12/12
  de la Portilla F [10](#jgh312141-bib-0010){ref-type="ref"}                                                                               2013       Yes                             One‐arm clinical trial           II/2                           MSC                                     24/6
  Wainstein C [34](#jgh312141-bib-0034){ref-type="ref"}                                                                                    2016       No                                Cohort univariable            ---/1                           MSC                                      9/4
  Garcia ‐Arranz M [35](#jgh312141-bib-0035){ref-type="ref"}                                                                               2016       Yes                             One‐arm clinical trial           II/1                           MSC                                     10/12
  Lightnert AL[‡](#jgh312141-note-0005){ref-type="fn"} [36](#jgh312141-bib-0036){ref-type="ref"}                                           2016       No                              One‐arm clinical trial           I/1                            MSC                                      7/6
  Moniuszko A[‡](#jgh312141-note-0005){ref-type="fn"} [37](#jgh312141-bib-0037){ref-type="ref"}                                            2015       No                                   Case series                ---/1                           MSC                                      1/1
  Panes J[‡](#jgh312141-note-0005){ref-type="fn"} [17](#jgh312141-bib-0017){ref-type="ref"}                                                2018       Yes          Panes J, 2016               RCT                    ---/2                      Placebo, MSC                                131/12
  Serrero M[‡](#jgh312141-note-0005){ref-type="fn"} [38](#jgh312141-bib-0038){ref-type="ref"}                                              2017       Yes                             One‐arm clinical trial           II/1                           MSC                                      9/3
  Park KJ [39](#jgh312141-bib-0039){ref-type="ref"}                                                                                        2015       Yes                             One‐arm clinical trial           I/1                            MSC                                      6/6
  Ciccocioppo R [40](#jgh312141-bib-0040){ref-type="ref"}                                                                                  2015       No        Ciccocioppo R, 2011     Cohort univariable            ---/1                           MSC                                     8/72
  Baixauli‐Fons J[‡](#jgh312141-note-0005){ref-type="fn"} [41](#jgh312141-bib-0041){ref-type="ref"}                                        2016       Yes                             One‐arm clinical trial           II/1                           MSC                                     15/12
  Dietz AB [42](#jgh312141-bib-0042){ref-type="ref"}                                                                                       2017       Yes                             One‐arm clinical trial           I/1                            MSC                                     12/6

Two MSC arms; cumulative results reported.

Abstract.

Sixty‐eight patients on MSC and 66 patients on fibrin glue arms included in meta‐analysis.

MSC, mesenchymal stem cells; RCT, randomized clinical trial.

As for the etiology, all studies included patients with CD fistulas, except one where patients with cryptoglandular fistulas were also enrolled[31](#jgh312141-bib-0031){ref-type="ref"} and one with only the last type included.[33](#jgh312141-bib-0033){ref-type="ref"} As shown in Table [2](#jgh312141-tbl-0002){ref-type="table"}, in the vast majority of studies, patients suffering from perianal fistulas were included, and MSCs were mainly autologous and mostly derived from adipose tissue.

###### 

Study clinical information

  First author        Year           Fistulas                  Type of fistula          Type of MSC     MSC source
  ------------------ ------ --------------------------- ------------------------------ ------------- ----------------
  Garcia‐Olmo D       2010             Crohn                     Rectovaginal           Autologous    Adipose tissue
  Cho YB              2013             Crohn                       Perianal             Autologous    Adipose tissue
  Lee WY              2013             Crohn                       Perianal             Autologous    Adipose tissue
  Choi S              2013             Crohn                       Perianal             Autologous    Adipose tissue
  Molendijk I         2015             Crohn                       Perianal             Allogeneic     Bone marrow
  Panes J             2016             Crohn                       Perianal             Allogeneic    Adipose tissue
  Garcia‐Olmo D       2005             Crohn                        Mixed               Autologous    Adipose tissue
  Garcia‐Olmo D       2003             Crohn                     Rectovaginal           Autologous    Adipose tissue
  Garcia‐Olmo D       2009   Cryptoglandular and Crohn              Mixed               Autologous    Adipose tissue
  Herreros MD         2012        Cryptoglandular                  Perianal             Autologous    Adipose tissue
  Ciccocioppo R       2011             Crohn             Perianal and enterocutaneous   Autologous     Bone marrow
  de la Portilla F    2013             Crohn                       Perianal             Allogeneic    Adipose tissue
  Wainstein C         2016             Crohn                       Perianal             Autologous    Adipose tissue
  Garcia ‐Arranz M    2016             Crohn                     Rectovaginal           Allogeneic    Adipose tissue
  Lightnert AL        2016             Crohn                       Perianal             Autologous    Adipose tissue
  Moniuszko           2015             Crohn                     Rectovaginal           Autologous    Adipose tissue
  Serrero M           2017             Crohn                       Perianal             Autologous    Adipose tissue
  Park KJ             2015             Crohn                       Perianal             Allogeneic    Adipose tissue
  Baixauli‐Fons J     2016             Crohn                        Mixed               Autologous    Adipose tissue
  Dietz AB            2017             Crohn                       Perianal             Autologous    Adipose tissue

MSC, mesenchymal stem cells.

Overall, 696 patients enrolled in the studies were meta‐analyzed: 494 were treated with MSCs, while 202 were in the control arm. The demographic and clinical characteristics of the enrolled patients are summarized in Table [3](#jgh312141-tbl-0003){ref-type="table"}. Half of the patients were male; the median age across studies was 36 years. The median disease duration was 10 years. Only a few studies provided information on CDAI and PDAI scores, smoking habits, comorbidities, or concomitant therapy. The dosage of MSC injections ranged from 1 to 9 × 10^7^ cells/mL or 20 to 120 × 10^6^ cells suspended in different volumes, thus preventing the statistical analysis.

###### 

Population characteristics: Distribution over studies (median \[25--75th\])

  Variable                                    Number of studies                Overall            MSC arm           Control arm
  ---------------------------------- ------------------------------------ ----------------- ------------------- -------------------
  Studies                             23 (inclusive of three substudies)         23                 23                   4
  Patients                                            23                         696                494                 202
  Percent male                                        17                     50 (40--60)        46 (22--60)      54.5 (51.5--65.5)
  Age (years)                                         16                   36.5 (33--41.5)    35 (32.5--39.5)     41 (37.5--47.5)
  CDAI                                                3                    92.7 (89--114)    102.7 (90.2--204)      85 (76--94)
  PDAI                                                3                    6.6 (5.2--6.8)      6.8 (4.4--13)      5.9 (5.2--6.6)
  Percent with comorbidities                          1                      75 (75--75)            75                  NA
  Heart                                               1                           0                  0                  NA
  Hypertension                                        1                           8                  8                  NA
  Diabetes                                            1                           0                  0                  NA
  Lung                                                1                           0                  0                  NA
  Kidney                                              1                          33                 33                  NA
  Liver                                               1                          50                 50                  NA
  Percent currently smoking                           1                     26.5 (20--33)       20 (20--20)             33
  Percent with concomitant therapy                    6                    88 (58.5--100)     97.5 (77--100)       60.5 (40--81)
  Steroid                                             3                    11.5 (5.5--25)       17 (5--33)           6 (6--6)
  Immunosuppressants                                  4                     46.5 (28--58)     50 (33.5--66.5)     39\. 5 (28--51)
  Biological drugs                                    7                       0 (0--61)         0 (0--100)         30.5 (0--61)
  Antibiotics                                         3                      39 (12--54)        54 (8--100)        25.5 (12--39)
  Disease duration (years)                            13                    10 (6.5--12)       10 (6.5--12)        8.9 (6.8--11)

CDAI, Crohn\'s disease activity index; MSC, mesenchymal stem cells; PDAI, perianal disease activity index.

Table [4](#jgh312141-tbl-0004){ref-type="table"} details the number of studies that evaluated a given end‐point. As shown, external healing was the efficacy end‐point most frequently evaluated (18 studies and all four comparative RCTs), together with fistula recurrence (10 studies and three of the RCTs). The presence of AEs or severe AEs, including mortality, was reported in the majority of the original studies (17/20), although the relationship with MSC therapy was less frequently assessed. Hospitalization was reported in five articles.

###### 

Number of studies with evaluable end‐points

  Number of studies                Overall   MSC arm  Control arm
  ------------------------------ --------- --------- -------------
  Safety                                             
  AE (patients)                         17        17       4
  Related AE (patients)                 12        12       3
  Severe related AE (patients)          17        17       4
  AE (numbers)                          14        14       2
  Related AE (numbers)                   7         7       1
  Severe related AE (numbers)            8         8       2
  Death acute                           20        20       4
  Death late                            19        19       4
  Hospitalization                        5         5       /
  Efficacy                                           
  External healing                      18        18       4
  Radiological healing                   7         7       1
  Endoscopic healing                     2         2       1
  Combined end‐point                     3         3       3
  CDAI                                   3         3       2
  PDAI                                   3         3       2
  Fistula recurrence                    10        10       3

AE, adverse events; CDAI, Crohn\'s disease activity index; PDAI, perianal disease activity index; MSC, mesenchymal stem cells.

*Results of individual studies and synthesis of results* {#jgh312141-sec-0012}
--------------------------------------------------------

The cumulative incidence of safety end‐points is reported in Tables [5](#jgh312141-tbl-0005){ref-type="table"} and [6](#jgh312141-tbl-0006){ref-type="table"}. AEs were observed in 53% of patients (34% in the observational studies and 61% in the clinical trials, Table [5](#jgh312141-tbl-0005){ref-type="table"}). In the four RCTs (Table [6](#jgh312141-tbl-0006){ref-type="table"}), the cumulative incidence of AEs was similar between the MSC arm (71%) and the control arm (66%), with an RR of 1.06 (95% CI: 0.93--1.22). Treatment‐related AEs (e.g. anal abscess and pain) occurred in 13% (95% CI: 5--24) in the MSC arm compared to 24% (95% CI: 14--35) in the control arm, with an RR of 0.65 (95% CI: 0.43--0.97) favoring the MSC arm. Similarly, severe treatment‐related AEs, which were rare, occurred less frequently in the MSC arm (1%, 95% CI: 0--2) than in the control arm (2%, 95% CI: 0--6). There were no fatal events. Individual and meta‐analysis rates of AEs are shown in Figures S2--S5, Supporting information.

###### 

Safety end‐points: Meta‐analytical estimates of cumulative incidence (95% confidence interval) (observational longitudinal studies and mesenchymal stem cell arm of trials)

  Safety end‐points                               Overall  Observational studies    Clinical trials                           
  --------------------------------------------- --------- ----------------------- ----------------- -------------------- ---- -------------------
  Proportion with AEs                                  17    0.53 (0.30 0.75)                     7  0.34 (0.00 ‐ 0.90)    10  0.61 (0.36--0.83)
  Treatment‐related                                    12    0.01 (0.00--0.07)                    3  0.00 (0.00--0.00)      9  0.04 (0.00--0.12)
  Severe treatment‐related                             17    0.00 (0.00--0.00)                    3  0.00 (0.00--0.00)     14  0.00 (0.00--0.01)
  Acute local                                           8    0.37 (0.00--0.86)                    1  0.00 (0.00--0.98)      7  0.41 (0.03--0.88)
  Acute systemic                                        7    0.00 (0.00--0.06)                    2  0.50 (0.00--1.00)      5  0.01 (0.00--0.07)
  Rate of late local AE/patient/month                   7    0.00 (0.00--0.01)                    2  0.01 (0.00--0.01)      5  0.00 (0.00--0.03)
  Rate of late systemic AE/patient/month                7    0.01 (0.00--0.03)                    1  0.00 (0.00--0.01)      6  0.02 (0.00--0.07)
  Number of AE/patient/month                           13    0.13 (0.05--0.24)                    5  0.00 (0.00--0.03)      8  0.26 (0.07--0.52)
  Treatment‐related                                     7    0.00 (0.00--0.01)                    2  0.00 (0.00--0.02)      5  0.01 (0.00--0.01)
  Severe treatment‐related                              8    0.00 (0.00--0.00)                    2  0.00 (0.00--0.00)      6  0.00 (0.00--0.00)
  Proportion acute death                               20    0.00 (0.00--0.00)                    5  0.00 (0.00--0.01)     15  0.00 (0.00--0.00)
  Rate of late death per person/month                  19    0.00 (0.00--0.00)                    4  0.00 (0.00--0.01)     15  0.00 (0.00--0.00)
  Rate of rehospitalization per person/months           5    0.01 (0.00--0.03)                    2  0.00 (0.00--0.00)      3  0.01 (0.01--0.08)

95% CI, 95% confidence interval; AE, adverse event; *N*, number of studies.

###### 

Safety end‐points: Meta‐analytical estimates of cumulative incidence (95% confidence interval) and relative risk in randomized clinical trials

  Variable                                                         *N*                      Incidence MSC arm (95% CI)   Incidence CTRL arm (95% CI)      RR (95% CI)
  -------------------------------------------- ------------------------------------------- ---------------------------- ----------------------------- -------------------
  Proportion with AEs                                               4                           0.71 (0.35--0.96)             0.66 (0.38--0.8)         1.06 (0.93--1.22)
  Treatment‐related                                                 3                           0.13 (0.05--0.24)             0.24 (0.14--0.35)        0.65 (0.43--0.97)
  Severe treatment‐related                      5[†](#jgh312141-note-0012){ref-type="fn"}       0.01 (0.00--0.02)             0.02 (0.00--0.06)                /
  Acute local                                                       2                           0.08 (0.03--0.16)             0.05 (0.00--0.13)                /
  Acute systemic                                                    2                           0.00 (0.00--0.03)             0.00 (0.00--0.01)                /
  Rate of late local AE/patient/month                               2                           0.00 (0.00--0.00)             0.00 (0.00--0.00)                /
  Rate of late systemic AE/patient/month                            2                           0.00 (0.00--0.03)             0.00 (0.00--0.00)                /
  Number of AE/patient/month                                        2                           0.52 (0.42--0.62)             0.46 (0.34--0.54)                /
  Treatment‐related                                                 1                           0.00 (0.00--0.00)             0.00 (0.00--0.19)                /
  Severe treatment‐related                                          2                           0.00 (0.00--0.02)             0.02 (0.00--0.06)                /
  Rate of rehospitalization per person month                        3                           0.04 (0.00--0.08)                     /                        /

One substudy.

95% CI, 95% confidence interval; AE, adverse event; CTRL, control; MSC, mesenchymal stem cells; *N*, number of studies; RR, relative risk.

The cumulative incidences of meeting efficacy end‐points are listed in Tables [7](#jgh312141-tbl-0007){ref-type="table"} and [8](#jgh312141-tbl-0008){ref-type="table"}. External healing (18 studies) occurred in 80% of patients (84% in the observational studies and 77% in the clinical trials, Table [7](#jgh312141-tbl-0007){ref-type="table"} and Fig. [2](#jgh312141-fig-0002){ref-type="fig"}a). In the four RCTs, (Table [8](#jgh312141-tbl-0008){ref-type="table"}, Fig. [2](#jgh312141-fig-0002){ref-type="fig"}b) external healing was observed in 64% of the MSC treated arm and 37% of the control arm, with an RR of 1.57 (95% CI: 1.07--2.31, Fig. [2](#jgh312141-fig-0002){ref-type="fig"}c) favoring the MSC arm. Similarly, in those studies assessing the combined external and radiological healing end‐point, the RR favored the MSC arm; RR 1.57 (95% CI: 1.07--2.31, Table [6](#jgh312141-tbl-0006){ref-type="table"}). The incidence of radiological healing (seven studies) was comparable (83% of patients) to that of external healing (Table [7](#jgh312141-tbl-0007){ref-type="table"}, Fig. S1a). The meta‐analytical incidence rate of fistula recurrence was 0, both in observational studies (95% CI: 0--1) and in clinical trials (95% CI: 0--4) (Fig. S1b,c), over a median follow‐up of 6 months (25--75th: 2.5--9 months).

###### 

Efficacy end‐points: Meta‐analytical estimates of cumulative incidence (95% confidence interval) (observational longitudinal studies and mesenchymal stem cell arm of trials)

  Efficacy end‐point                         Overall    Observational studies      Clinical trials                                  
  ---------------------------------------- --------- --------------------------- ----------------- --------------------------- ---- ---------------------------
  Proportion with external healing                18     0.80 (0.70 to 0.89)                     5      0.84 (0.58--1.00)        13      0.77 (0.67--0.89)
  Partial                                         14     0.22 (0.10 to 0.36)                     4     0.14 (0.00 to 0.43)       10     0.25 (0.12 to 0.40)
  Total                                           16    0.51 (00.40 to 0.62)                     5     0.56 (0.28 to 0.83)       11     0.50 (0.38 to 0.62)
  Proportion with radiological healing             7     0.83 (0.65 to 0.96)                     2     0.72 (0.50 to 0.90)        5     0.88 (0.65 to 1.00)
  Proportion with endoscopic healing               2     0.17 (0.04 to 0.35)                     1     0.58 (0.28 to 0.85)        1     0.00 (0.00 to 0.22)
  Proportion with combined response                3     0.48 (0.40 to 0.57)                     0              /                 3     0.48 (0.40 to 0.57)
  Rate of recurrence (per person months)          10     0.00 (0.00 to 0.01)                     4     0.00 (0.00 to 0.03)        6     0.00 (0.00 to 0.04)
                                                      **Median (25 to --75th)**                     **Median (25 to --75th)**        **Median (25 to --75th)**
  Change in CDAI                                   3      12 (−5.7 to 195)                       1      195 (195 to 195)          2    3.15 (−5.7 to 12.00)
  Change in PDAI                                   3      2.3 (1.8 to 8.5)                       1      8.5 (8.5 to 8.5)          2     2.05 (1.80 to 2.30)

95% CI, 95% confidence interval; CDAI, Crohn\'s disease activity index; *N*, number of studies; PDAI, perianal disease activity index.

###### 

Efficacy end‐points: Meta‐analytical estimates of cumulative incidence (95% confidence interval) and relative risk (RR) in randomized clinical trials

  Variable                                  Number of RCTs   Incidence MSC arm (95% CI)   Incidence CTRL arm (95% CI)       RR (95% CI)
  ---------------------------------------- ---------------- ---------------------------- ----------------------------- ---------------------
  Proportion with external healing                4             0.64 (0.57 to 0.70)           0.37 (0.21 to 0.55)       1.54 (1.03 to 2.29)
  Partial                                         3             0.22 (0.06 to 0.44)           0.09 (0.04 to 0.15)       2.06 (0.60 to 7.04)
  Total                                           3             0.42 (0.24 to 0.62)           0.25 (0.04 to 0.55)       1.34 (1.02 to 1.77)
  Proportion with radiological healing            1             0.53 (0.27 to 0.79)           0.27 (0.00 to 0.64)                /
  Proportion with endoscopic healing              1             0.00 (0.00 to 0.22)           0.00 (0.00 to 0.48)                /
  Proportion with combined response               3             0.48 (0.40 to 0.57)           0.35 (0.29 to 0.41)       1.57 (1.07 to 2.31)
  Rate of recurrence (per person months)          3             0.00 (0.00 to 0.02)           0.00 (0.00 to 0.01)                /
                                                             **Median (25 to --75th)**     **Median (25 to --75th)**          **SMD**
  Change in CDAI                                  2            3.15 (−5.70 to 12.00)       −28.10 (−54.00 to −2.20)              /
  Change in PDAI                                  2             2.05 (1.80 to 2.30)          0.50 (−0.30 to 1.30)                /

95% CI, 95% confidence interval; CDAI, Crohn\'s disease activity index; CTRL, control; MSC, mesenchymal stem cells; *N*, number of studies; PDAI, perianal disease activity index; RCT, randomized clinical trial; RR, relative risk: SMD, standardized mean difference.

![(a) Cumulative incidence of clinical healing by study design. Diamonds represent the meta‐analytical estimate of the cumulative incidence (95% CI) of clinical healing for observational studies (OBS), for clinical trials (TRIAL), and overall. Dots and whiskers represent the incidences and 95% CIs derived from the single studies. The dotted vertical line corresponds to the overall incidence. (b) Cumulative incidence of clinical healing by treatment arm in the four randomized clinical trials (RCTs). (c) Relative risk (RR) of healing in the four RCTs. The diamond represents the meta‐analytical estimate of the RR (95% CI) of clinical healing. Dots and whiskers represent the RRs and 95% CIs derived from the single studies. The continuous vertical line corresponds to null effect, the dotted vertical line to the meta‐analytical RR.](JGH3-3-249-g002){#jgh312141-fig-0002}

*Risk of bias* {#jgh312141-sec-0013}
--------------

None of the observational studies and single‐arm trials was controlled for confounding, mostly due to the low number of patients included in each study. Randomization and concealment was adequate in three RCTs but was unclear or not described in the other cases. The assessment of missing data was unclear or not considered in 10 studies, and reporting was lacking in 16 studies. The subjective assessment of the risk of bias across all studies yielded a median VAS of 22 (25--75th: 11--60). No evidence of publication bias was elicited from the funnel plots of the RCTs (Fig. [3](#jgh312141-fig-0003){ref-type="fig"}) when considering the efficacy end‐points, external healing and the clinical composite, or the safety end‐points, AEs and treatment‐related AEs.

![Funnel plots for the identification of publication bias for the efficacy end‐points in terms of clinical healing (a) and combined healing (b) and for the safety end‐points in terms of adverse events (c) and treatment‐related adverse events (d). (LN_IRR, log‐transformed incidence rate ratio; s.e., standard error).](JGH3-3-249-g003){#jgh312141-fig-0003}

Discussion {#jgh312141-sec-0014}
==========

MSC therapy is an emerging potential treatment for a number of medical conditions triggered and sustained by a dysregulated immune response resulting in tissue damage.[15](#jgh312141-bib-0015){ref-type="ref"} This systematic literature review with meta‐analysis was conducted to assess the safety and efficacy of MSC local injections in fistulas (most perianal) of both CD and cryptoglandular origin, thus providing information to clinicians and patients considering this treatment option. Our analysis clearly shows that the use of MSCs results in a high rate of external and radiological healing in patients with perianal CD, up to 80% in observational studies and 64% in RCTs, with treatment‐related AEs seen in approximately 1% of patients. Remarkably, fistula healing appears durable, with isolated recurrences over a 6‐month time period. Among RCTs, MSC treatment results in an estimated 50% higher rate of fistula healing compared to the control arm. Conversely, the proportion of MSC‐treated patients with AEs is similar to controls. This evidence supports the concept that MSC local injections represent an important step forward in ameliorating patient outcomes, avoiding current invasive surgical procedures, which result in postoperative complications in a substantial number of cases.[43](#jgh312141-bib-0043){ref-type="ref"}, [44](#jgh312141-bib-0044){ref-type="ref"} In addition, the surgical technique applied (seton placement, obturation with fibrin glue or plug, mucosal advancement flap, muscle transposition, ligation of the inter‐sphincteric tract, sphincteroplasty) differs among centers depending on personal experience and preference, resulting in disparate outcomes.[45](#jgh312141-bib-0045){ref-type="ref"} For medical therapy, the efficacy of biological agents in terms of complete fistula closure was 64% for infliximab at week 14[46](#jgh312141-bib-0046){ref-type="ref"} and approximately 30% for adalimumab at week 26[47](#jgh312141-bib-0047){ref-type="ref"} and for vedolizumab at week 14,[48](#jgh312141-bib-0048){ref-type="ref"} while no definitive data are available for ustekinumab.[49](#jgh312141-bib-0049){ref-type="ref"}, [50](#jgh312141-bib-0050){ref-type="ref"} With longer follow‐up (around 1 year), these values fell to 23, 33, and 16%, respectively. For thiopurines, a meta‐analysis showed that the efficacy rate after a mean follow‐up of 26 weeks was 54%, with a pooled odds ratio of 4.44 (95% CI: 1.50--13.20) favoring fistula healing.[51](#jgh312141-bib-0051){ref-type="ref"} Previously, antibiotics were used as first‐line therapy but did not result in fistula closure.[52](#jgh312141-bib-0052){ref-type="ref"}

A contributing factor to the difficulty in fistula treatment is the uncertainty of its pathogenesis.[1](#jgh312141-bib-0001){ref-type="ref"} It is clear that immune mechanisms are only one component, and additional factors, such as the supportive stroma and the microvascular bed, favor the development and maintenance of tissue damage. In this regard, MSCs are known to exert a multifaceted action not only on those cells involved in immune response but also on epithelial cells, capillaries, and stroma (for review, see Ciccocioppo *et al*.[53](#jgh312141-bib-0053){ref-type="ref"}). Currently, the precise mechanism of action of MSCs in fistula healing is not well understood. In the few studies addressing the mechanism of action of MSCs in fistula,[9](#jgh312141-bib-0009){ref-type="ref"}, [30](#jgh312141-bib-0030){ref-type="ref"}, [35](#jgh312141-bib-0035){ref-type="ref"} an increase of T‐cells with regulatory function at both rectal mucosa and peripheral blood level was evident.[9](#jgh312141-bib-0009){ref-type="ref"} However, no modification of cytokine profile was found at the rectal level[30](#jgh312141-bib-0030){ref-type="ref"} or in peripheral blood,[35](#jgh312141-bib-0035){ref-type="ref"} although neither interleukin‐13 nor transforming growth factor‐β, both considered key molecules in fistula pathogenesis,[1](#jgh312141-bib-0001){ref-type="ref"} were assessed.

Nonetheless, our evidence was obtained from a sizable number of patients (494 with MSCs and 202 with comparator), with 412 of them recruited in two RCTs.[16](#jgh312141-bib-0016){ref-type="ref"}, [33](#jgh312141-bib-0033){ref-type="ref"} We found a striking effect of MSCs in inducing external healing of the fistula tracks, with a cumulative rate of 80% in the short term. When assessing data from observational studies in comparison to RCTs, the healing rate was similar (84% *versus* 77%). It is conceivable that the lack of imaging evaluation in several early studies may have led to an overestimation of benefit; however, when performed, radiological assessment was generally consistent with the clinical evaluation. Finally, an improvement of the clinical indexes of activity, CDAI and PDAI, in the studies where they were assessed is demonstrated, whereas only a few studies evaluated mucosal healing.[9](#jgh312141-bib-0009){ref-type="ref"}, [10](#jgh312141-bib-0010){ref-type="ref"} In our opinion, this is an important end‐point as rectal inflammation sustains fistula formation.[54](#jgh312141-bib-0054){ref-type="ref"} Accordingly, we found that mucosal healing paralleled fistula closure,[9](#jgh312141-bib-0009){ref-type="ref"} whereas in the darvadstrocel phase III trial, the presence of active inflammation of the rectal mucosa was an exclusion criterion.[16](#jgh312141-bib-0016){ref-type="ref"}

A further interesting point is that the results were invariably favorable despite differences in the anatomy of fistulas (anal, rectovaginal, entercutaneous), etiology (CD and/or cryptoglandular), assessment time point, MSC source, HLA setting, dose, and schedule of injections. This is critical as allogeneic MSCs have the advantage of being widely available without the infrastructure and lag time needed for the production of autologous clinical‐grade MSCs.[55](#jgh312141-bib-0055){ref-type="ref"} Overall, a wide heterogeneity in dosage was observed in the reported articles; thus, the impact of MSC dosage on efficacy has not yet been established. However, no evidence of a clear dose‐dependent efficacy was observed in the studies where dose escalation was performed.[10](#jgh312141-bib-0010){ref-type="ref"}, [11](#jgh312141-bib-0011){ref-type="ref"}, [27](#jgh312141-bib-0027){ref-type="ref"}, [29](#jgh312141-bib-0029){ref-type="ref"}, [30](#jgh312141-bib-0030){ref-type="ref"}, [31](#jgh312141-bib-0031){ref-type="ref"}, [35](#jgh312141-bib-0035){ref-type="ref"}, [39](#jgh312141-bib-0039){ref-type="ref"} Therefore, a definitive conclusion about optimal dosing cannot be drawn, and standardization of both cellular concentration and total volume to be injected are important issues that need to be addressed.[55](#jgh312141-bib-0055){ref-type="ref"} In this regard, an adaptation of both the MSC dosage and number of injections was performed in two studies[9](#jgh312141-bib-0009){ref-type="ref"}, [11](#jgh312141-bib-0011){ref-type="ref"} in an attempt to address this specific issue.

Long‐standing disease does not seem to hamper MSC efficacy as the mean duration in the studies evaluated was 10 years (range 6.5--12). Whether treating with MSC earlier on in the disease prevents organ dysfunction and if using serial injections instead of single administration reduces the recurrence rate are important issues that remain to be determined. In this regard, we found an irrelevant rate of fistula recurrence on a median follow‐up of 6 months even though, in all studies, the patients enrolled had had an inadequate response to conventional or biological therapy. In contrast, the probability of fistula relapse‐free survival, defined as the percentage of patients who do not need to restart medical therapy, decreases progressively over time,[56](#jgh312141-bib-0056){ref-type="ref"} reaching at 88% at 1 year, 50% at 2 years, and 37% at 5 years.[40](#jgh312141-bib-0040){ref-type="ref"} However, these rates are more favorable than those observed after biological[46](#jgh312141-bib-0046){ref-type="ref"}, [47](#jgh312141-bib-0047){ref-type="ref"}, [48](#jgh312141-bib-0048){ref-type="ref"}, [49](#jgh312141-bib-0049){ref-type="ref"}, [50](#jgh312141-bib-0050){ref-type="ref"} or surgical[57](#jgh312141-bib-0057){ref-type="ref"} therapy.

In contrast with CD fistulas, only scant information is available on the safety and efficacy of MSC local treatment in cryptoglandular complex perianal fistulas. Indeed, this condition was explored in only three studies[29](#jgh312141-bib-0029){ref-type="ref"}, [31](#jgh312141-bib-0031){ref-type="ref"}, [33](#jgh312141-bib-0033){ref-type="ref"} with contrasting results: in two studies, the MSC injection proved to be successful in achieving fistula healing at week 8 \[69.2%[29](#jgh312141-bib-0029){ref-type="ref"} and 71%[31](#jgh312141-bib-0031){ref-type="ref"}\], and in one study, no apparent benefit was shown.[33](#jgh312141-bib-0033){ref-type="ref"} However, when dissecting these last results among the participating centers, the analysis carried out on the subpopulation treated at the leading center showed healing rates of 54.55 and 83.33% when using MSC treatment alone or in combination with fibrin glue, respectively, compared to 18.18% when using fibrin glue alone,[33](#jgh312141-bib-0033){ref-type="ref"} thus highlighting the need for standardization techniques and training.

Considering safety, it is widely known that conventional immunosuppressive and immunomodulant therapies are associated with severe AEs, including opportunistic infections and the potential for malignancy.[58](#jgh312141-bib-0058){ref-type="ref"} In contrast, the safety profile of MSCs appears favorable. The most frequently reported treatment‐related AEs were anal abscess and proctalgia that developed in 17.5 and 29.4% of the MSC and placebo arm, respectively, in the pivotal phase III trial and were attributed to the surgical procedure.[16](#jgh312141-bib-0016){ref-type="ref"} Moreover, although 53 of 107 MSC‐treated patients developed anti‐HLA class I antibodies, there was no association with positivity for donor‐specific antibodies and AEs or therapeutic response.[16](#jgh312141-bib-0016){ref-type="ref"} The most important issue when evaluating the long‐term safety of cellular therapies is malignancy. In this regard, a potential carcinogenic risk had been postulated based on the *in vitro* demonstration of MSC malignant transformation.[59](#jgh312141-bib-0059){ref-type="ref"}, [60](#jgh312141-bib-0060){ref-type="ref"} However, this finding was subsequently refuted by the same authors and explained by cross‐culture contamination.[61](#jgh312141-bib-0061){ref-type="ref"}, [62](#jgh312141-bib-0062){ref-type="ref"} When moving to *in vivo* results, our data confirmed previous evidence of absence of cancer development among patients who underwent intravascular MSC treatment,[63](#jgh312141-bib-0063){ref-type="ref"} and neither ectopic growth of tissues nor opportunistic infections have been recorded. Possibly, the absence of long‐term engraftment might protect against this risk, while the anti‐inflammatory effect might contribute to reducing the risk of tumor development. Indeed, patients with perianal fistulas in CD have an increased risk of malignancy,[64](#jgh312141-bib-0064){ref-type="ref"}, [65](#jgh312141-bib-0065){ref-type="ref"}, [66](#jgh312141-bib-0066){ref-type="ref"} with the inflammatory milieu being the main driving force.[67](#jgh312141-bib-0067){ref-type="ref"} Finally, neither fertility nor pregnancy has been shown to be affected by MSC local therapy.[68](#jgh312141-bib-0068){ref-type="ref"}

In conclusion, despite the lack of standardization in the collection of end‐points and information derived mostly from uncontrolled observational studies and one‐arm clinical trials, the possibility of achieving sustained fistula closure with favorable safety makes MSCs an attractive therapeutic strategy for patients with perianal fistulas in CD. Therefore, local MSC therapy should appropriately be placed in the treatment algorithm of this condition. Further studies aimed at assessing dosage and schedule of MSC injections, functional potency of the cellular suspension, donor heterogeneity, implementation of the manufacturing process, and efficacy of this treatment in comparison with biologics using standardized safety and efficacy end‐points are required. Finally, although the cost‐effectiveness was beyond the scope of this work, this represents a crucial point that needs to be appropriately investigated.
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###### 

**Figure S1** (a) Cumulative incidence of radiological healing by study design, (b) of fistula recurrence by study design, and (c) of fistula recurrence by treatment arm in the four randomized clinical trials. Diamonds represent the meta‐analytical estimate of the cumulative incidence (95% confidence interval \[95% CI\]). Dots and whiskers represent the incidences and 95% CI derived from the single studies. The dotted vertical line corresponds to the overall incidence.

**Figure S2** (a) Cumulative incidence of adverse events by study design, (b) of treatment related adverse events by study design, and (c) of severe treatment related adverse events by study design.

**Figure S3** (a) Cumulative incidence of local acute adverse events by study design, (b) of systemic acute adverse events by study design, (c) incidence of local late adverse events by study design, and (d) of systemic late adverse events by study design.

**Figure S4** (a) Incidence of hospitalization by study design; (b) acute mortality by study design; and (c) late mortality by study design.

**Figures S5** (a) Incidence of adverse events by treatment arm in randomized clinical trials, (b) of treatment‐related adverse events by treatment arm in randomized clinical trials, and (c) of severe treatment‐related adverse events by treatment arm in randomized clinical trials.

**Table S1A** Search strategy 1 (performed on 2017‐05‐13).

**Table S1B** Search strategy 2 (performed on 2017‐05‐13).
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